Short answer
Amphastar Pharmaceuticals, Inc. (AMPH) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $184M (up 5.4% year over year) with net income of $30M.
Q2 2026 key financials · XBRL
- Revenue
- $184M
- +5.4% YoY · +7.4% QoQ
- Net income
- $30M
- −2.2% YoY · +372.7% QoQ
- Operating margin
- 21.6%
- Gross margin
- 50.8%
- EPS (diluted)
- $0.67
- +4.7% YoY · +378.6% QoQ
Source: XBRL data from the Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 10-Q on SEC EDGAR. USD.
Amphastar Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered FDA warning letter: IMS’s South El Monte facility received a July 2, 2026 letter citing finished-pharmaceutical cGMP violations
- Regulatory remediation risk: IMS voluntarily suspended one product while prioritizing products at shortage risk
- Operational risk: FDA may pursue additional action if IMS deficiencies remain unresolved
- Financial market risk: Lenders’ collateral includes 5,700,000 pledged shares, potentially pressuring Amphastar’s stock price
- Concentration risk: UBS can unilaterally call $15.0 million in credit lines for any reason
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amphastar Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.